Alliances
Help Us Shape the Future of Medicines
To realize our mission of translating a great scientific idea into a real, transformative medicine for patients, we rely on external partners who bring expertise, investment, and scaling capacity to our pipeline. It’s these critical partnerships that ensure there is a path to patients beyond the walls of Stanford.
“The IMA continues to seek high-quality partners in our mission as an accelerator, and we are excited about engaging diverse partners in helping us scale Stanford-grown solutions.”
Chaitan Khosla
Director
Featured Alliances
Learn more about some of the alliances that are critical to our success.
OmniAb
OmniAb® provides partners access to the most diverse antibody repertoires and cutting-edge screening technologies to enable discovery of next-generation therapeutics.
Celltaxis
Celltaxis and the IMA are collaborating to test a new medicine for lymphedema.
Vergent Bioscience
This collaboration enables the clinical testing of imaging agents to improve surgical outcomes.
The Invus Group
The investment firm is supporting the development of treatments for glioblastoma.
Intonation Research Laboratories
This collaboration with Intonation, a contract research organization, aims to develop treatments for neuroendocrine tumors.
Alloy Therapeutics
Alloy’s immunocompetent transgenic mice enable best-in-class in vivo human antibody discovery.
Simcere Pharmaceutical
This collaboration with Simcere Pharmaceutical enables the lead identification of a novel therapeutic for Parkinson’s disease.
Twist Bioscience
Twist’s “Library of Libraries” and other services accelerate the discovery of antibody and other biologics-focused therapies.
Porter Alliance for Innovative Medicines
This collaboration with Deerfield Management Company supports projects with the potential to cure life-altering diseases.
Featured Projects
Acebilustat for lymphedema
Alliance: Celltaxis Lyphedema is a common, progressive disease that associated with chronic inflammation and skin thickening and leads to recurrent infections that result in hospitalizations. There is no current, definitive cure. Stanley Rockson and team recently demonstrated the central role of leukotriene B4 (LTB4), chemoattractant and proinflammatory agent, in the pathogenesis and maintenance of […]
Fluoxetine analog for glioblastoma therapy
Alliance: The Invus Group Despite growing knowledge around the genome alterations associated with glioblastoma, existing treatments have little therapeutic benefit and are aggressive, leaving patients suffering. Glioblastoma represents a particularly daunting problem because potential drugs need to penetrate the blood-brain barrier. Paul Mischel sought to find an Achilles heel, a potential liability for the […]
Come on Board
Our partners are critical to our success.
Looking to start an alliance with us? Have questions?
Contact Alliance Director Paul Humphries.
Related Articles
Stanford University and The Invus Group collaborate to develop glioblastoma drugs
Stanford University’s Innovative Medicines Accelerator and Intonation Research Laboratories form a collaboration to fight cancerous neuroendocrine tumors
Deerfield, Stanford University create Porter Alliance for Innovative Medicines
Stanford University and The Invus Group collaborate to develop glioblastoma drugs
Stanford University’s Innovative Medicines Accelerator and Intonation Research Laboratories form a collaboration to fight cancerous neuroendocrine tumors